This article was originally published in SRA
Finnish National Medicines Agency prepares to be a centre of excellence
You may also be interested in...
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
Attendees to Medicines for Europe’s Regulatory Affairs and Pharmacovigilance virtual conference heard that a window of opportunity to optimize the region’s regulatory landscape is now “wide open” with the advent of the new EU Pharmaceutical Strategy.
EY’s M&A Firepower report predicts very active M&A activity for medtechs in 2021, driven by diagnostics and digital health, but with some headwinds remaining.